Brief: Sana Biotechnology Confirms Key Program Timelines And Announces Portfolio Prioritization

Sana Biotechnology

29/11/2022 21:21

Nov 29 (Reuters) - Sana Biotechnology Inc  SANA.O :
    * SANA BIOTECHNOLOGY CONFIRMS KEY PROGRAM TIMELINES AND
ANNOUNCES
PORTFOLIO PRIORITIZATION
    * EXPECTS TO FILE IND THIS YEAR FOR SC291 WITH POTENTIAL
CLINICAL
DATA IN 2023
    * EXPECTS TO FILE INDS FOR SG295 AND SC263 IN 2023; SC451
AND
BCMA-TARGETED CAR T IN 2024
    * CO WILL DISCONTINUE INTERNAL INVESTMENT FOR SC187
(CARDIOMYOCYTES IN HEART FAILURE)
    * PRIORITIZATION AND RESTRUCTURING RESULTS IN HEADCOUNT
REDUCTION
OF APPROXIMATELY 15%

Source text for Eikon:  ID:nGNX9PVFBG 
Further company coverage:  SANA.O 
 ((Reuters.Briefs@thomsonreuters.com
))